Synspira, a Boston, MA-based company developing a new class of glycopolymer-based therapeutics for pulmonary disease, secured $8m in funding.
The company intends to use the funds to advance a Phase 1 first-in-humans safety study of SNSP113.
Founded in early 2017 by Shenda Baker, Ph.D., CEO, Synspira develops inhaled therapies for pulmonary diseases, such as cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD) and pneumonia through an exclusive field license to Synedgen’s Glycomics Technology Platform and their related pulmonary delivery assets.
The characteristics of its proprietary modified polysaccharide agents have the potential to address a major unmet need associated with these pulmonary disorders, the chronic infection and related inflammation which often lead to exacerbations, hospitalizations and ultimately irreversible lung function decline.
Synspira’s lead program, SNSP113, is an inhaled glycopolymeric agent designed for treating exacerbations and infections related to cystic fibrosis.
The company also announced the appointment of William Wiesmann, M.D., as Synspira’s Chairman of the Board. Dr. Baker, Andrew W. Miller, President and CEO of Stimson Lumber Company and Glenn Batchelder, Executive Chairman of XyloCor Therapeutics, will join Dr. Wiesmann on Synspira’s founding Board of Directors.